Testing for the full spectrum of hematologic disorders
Our comprehensive test menu has been created to aid in diagnosis and treatment selection across the full spectrum of hematologic disorders. Through our clinical experience, we have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly hematology testing newsletter.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
hematology and hematopathology tests performed annually
hematologists and hematopathologists on staff at Mayo Clinic
hematology-focused algorithms to guide test ordering
support from Mayo Clinic physicians and scientists
Innovation and collaboration between experts
Our laboratories are led by board-certified hematopathologists who focus on molecular diagnostics and prognostics of hematologic disorders, reviewing cases to provide interpretation of results related to clinically relevant genes. These experts are on call 24/7, so they are available any time you need answers.
The right test
at the right time
More than 30 hematology-focused algorithms are integrated directly into our testing approaches to ensure the right tests are being ordered at the right time. This approach simplifies the ordering process, arriving at clinically actionable answers for your patients, faster.
Our testing is supported by a round-the-clock staff of expert laboratory directors and genetic counselors who assist with everything from test ordering to results interpretation. Our experts collaborate closely with clients, not only to reach the right answers for current patients, but also to guide the development of future testing.
A Case-Based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis
Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and literature, we will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
Kenneth Hobby assumed his fever, fatigue, and aching pains in May 2018 were from another bout of malaria. He was on one of his frequent visits to Zambia in southern Africa, where the mosquito-borne parasite is common. But anti-malaria drugs didn't help, and soon Kenneth had such disabling pain that he could barely walk.
Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.
Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the diagnosis of heparin induced thrombocytopenia, or HIT, which can have devastating consequences for patients.
In this month's "Hot Topic," Rajiv Pruthi, M.B.B.S., discusses heparin induced thrombocytopenia (HIT), approach diagnosis, and the role of the functional serotonin release assay (SRA).
In this month's "Hot Topic," Jess Peterson, M.D., discusses changes to Mayo Clinic Laboratories’ hematology FISH menu to increase awareness, provide reasoning, and highlight some of the great things that are coming.